Subgroup sample size may have limited the detection of small to moderate risk associations but, taken together, our findings do not support a major role for these biomarkers in the development of specific subtypes of CRC based on KRAS and BRAF mutations or MSI status in the tumor. This evidence concerns the gene BRAF and colorectal carcinoma.